Skip to Content
Merck
CN

D4681

L-threo-Dihydrosphingosine

≥95% (TLC)

Synonym(s):

Safingol

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C18H39NO2
CAS Number:
Molecular Weight:
301.51
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352211
MDL number:
Assay:
≥95% (TLC)
Form:
powder
Quality level:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Quality Level

assay

≥95% (TLC)

form

powder

storage temp.

−20°C

SMILES string

CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO

InChI

1S/C18H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h17-18,20-21H,2-16,19H2,1H3/t17-,18-/m0/s1

InChI key

OTKJDMGTUTTYMP-ROUUACIJSA-N

Biochem/physiol Actions

Sphingosine kinase inhibitor; protein kinase C alpha (PKCα) -specific inhibitor; Sphingosine analog; potentiates the effect of doxorubicin (DOX) in tumor-bearing animals.


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



G K Schwartz et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 3(4), 537-543 (1997-04-01)
We performed a pilot clinical trial with safingol (L-threo-dihydrosphingosine), a protein kinase C-specific inhibitor that potentiates the effect of doxorubicin (DOX) in tumor-bearing animals. Safingol was initially administered as a 1-h infusion at escalating doses. Fourteen days later, patients received
J W Darges et al.
Advances in experimental medicine and biology, 400A, 387-392 (1997-01-01)
The sphingosine analog L-threo-dihydrosphingosine has been shown to inhibit protein kinase C (PKC) isoenzymes in mixed micelle and vesicle assays. This compound also inhibited the reactive oxygen intermediates (ROI) released from isolated neutrophils (IC50 approximately 2 microM) and phorbol ester-induced
Yi-Hsin Hsu et al.
Cancer research, 74(17), 4822-4835 (2014-06-28)
Triple-negative breast cancer (TNBC) is a highly heterogeneous and recurrent subtype of breast cancer that lacks an effective targeted therapy. To identify candidate therapeutic targets, we profiled global gene expression in TNBC and breast tumor-initiating cells with a patient survival



Global Trade Item Number

SKUGTIN
D4681-1MG04061833574034